Glenmark Pharmaceuticals, a Rs 2,000 crore plus pharmaceutical giant, has suffered heavy setback during the year ended March 2009 on account of slower growth in top line, higher interest burden as well as employees cost and the absence of outlicensing revenue due to overall global recession.
The details can be read here.
No comments:
Post a Comment